Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trans Sodium Crocetinate for Prevention of Contrast-Induced Nephropathy
IRCT20081019001369N8Phase 2Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of trans sodium crocetinate in contrast-induced nephropathy (CIN) and myocardial infarction (MI), sponsored by Mashhad University of Medical Sciences. Started Apr 2022; status: completed.
02
Drugs
trans sodium crocetinate
03
Conditions
contrast-induced nephropathy (CIN)myocardial infarction (MI)
Beyond the preview
Go deeper on IRCT20081019001369N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20081019001369N8.